Gilead Sciences, Inc. on Friday said the European Commission has granted conditional marketing authorization for remdesivir, also known as veklury, as a treatment for Covid-19. The authorization was based on a rolling review of supporting data that began in April 2020. Remdesivir is used to treat Covid-19 in adults and adolescents aged 12 years and older and weighing at least 40 kg, with pneumonia requiring supplemental oxygen. A European conditional marketing authorization is initially valid for one year but can be extended or turned into unlimited marketing authorization after the submission and assessment of additional confirmatory data.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Gilead granted conditional approval for Covid-19 treatment remdesivir in Europe
Latest posts by Market Watch (see all)